Extended Data Table 3 Immune-related adverse events (irAEs) (occurring in ≥ 2% of patients) and grade 3-5 irAEs (occurring in at least one patient)

From: First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial

  1. Data cutoff date: May 27, 2024.
  2. Sac-TMT, Sacituzumab tirumotecan; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TSH, thyroid-stimulating hormone.
Back to article page